The new European patent expands the available Zenvia dose ranges under prior patent protection and encompasses the company’s current clinical development programs in pseudobulbar affect and diabetic peripheral neuropathic pain, as well as other neurologic conditions.
Keith Katkin, president and CEO of Avanir, said: “This new patent significantly extends the period of Zenvia commercial exclusivity throughout Europe and enhances the global potential of our primary asset.”